Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07), FiscalAI reports.
Seaport Therapeutics Trading Up 0.9%
Shares of Seaport Therapeutics stock opened at $20.65 on Tuesday. The business’s 50 day moving average is $19.36. The firm has a market cap of $1.11 billion and a PE ratio of -2.00. Seaport Therapeutics has a 1-year low of $14.85 and a 1-year high of $23.00.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on SPTX shares. Citigroup assumed coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price target on the stock. Wolfe Research initiated coverage on shares of Seaport Therapeutics in a research note on Tuesday, July 7th. They set a “hold” rating on the stock. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a report on Saturday, May 9th. Seaport Research Partners set a $50.00 target price on shares of Seaport Therapeutics in a research report on Wednesday, July 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Seaport Therapeutics in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Seaport Therapeutics currently has an average rating of “Hold” and an average price target of $38.40.
Insider Activity
In other news, Director Robert J. Hombach acquired 13,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the completion of the acquisition, the director owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry.
See Also
- Five stocks we like better than Seaport Therapeutics
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
